scholarly journals B-Type Natriuretic Peptide Assay for Complex Congenital Heart Diseases

2013 ◽  
Vol 61 (19) ◽  
pp. 2022-2023
Author(s):  
Massimiliano Cantinotti ◽  
Michele Emdin ◽  
Aldo Clerico
Keyword(s):  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Heart Diseases ◽  
Congenital Heart Diseases

Plasma Atrial Natriuretic Peptide in Patients With Congenital Heart Diseases

PEDIATRICS ◽  
1988 ◽  
Vol 82 (4) ◽  
pp. 639-643
Author(s):  
Suguru Matsuoka ◽  
Yoshihide Kurahashi ◽  
Yohko Miki ◽  
Masuhide Miyao ◽  
Yasuhiro Yamazaki ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Septal Defect ◽  
Heart Diseases ◽  
Ductus Arteriosus ◽  
Right Atrial ◽  
Congenital Heart Diseases ◽  
Septal Defects ◽  
Atrial Natriuretic

The plasma level of human α-atrial natriuretic peptide was measured in healthy children and patients, 1 month to 15 years of age, with congenital heart diseases. Significant increases were found in patients with a ventricular septal defect, tricuspid valve atresia, patent ductus arteriosus, and atrial septal defect but not in those with pulmonary valve stenosis or tetralogy of Fallot. The levels were significantly higher in children with ventricular septal defects (221 ± 123 pg/mL) or patent ductus arteriosus (124 ± 38 pg/mL) than in those with atrial septal defects (65 ± 42 pg/mL) (P < .01). The increased levels appeared to be correlated with enlargement of the left atrium (r = .85, P < .01) but not with the right atrial size or the mean right atrial pressure. They were higher in younger than in older healthy infants, but this age difference did not affect the results. These findings indicate that human α-atrial natriuretic peptide is released into the circulation in response to chronic atrial expansion in patients with congenital heart disease and may have an important role in volume homeostasis.

scholarly journals The diagnostic and prognostic role of amino-terminal pro-brain type natriuretic peptides in pediatric cardiac diseases and pulmonary hypertension

2021 ◽  
Vol 5 (Volume 1) ◽  
pp. 21
Author(s):  
Kayirnisa Tilemanbetova ◽  
Taalaibek Kudaiberdiev ◽  
Jalil Sheishenov ◽  
Damirbek Abibillaev
Keyword(s):  
Congenital Heart Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Pediatric Patients ◽  
Heart Diseases ◽  
Congenital Heart Diseases ◽  
Amino Terminal

Objective: Several studies showed that N-terminal pro-brain type natriuretic peptide (NT-pro-BNP) as the reliable marker both in diagnostic and prognostic workup of pediatric patients with congenital heart disease complicated by pulmonary hypertension. Furthermore, it has well assisted both in therapeutic and surgical management of children with congenital heart diseases. In this review, we aimed to analyze recent studies concerning the role of the NT-pro-BNP in pediatric cardiac patients with pulmonary hypertension. Methods: PubMed, Cochrane, Science Direct and Google Scholar databases were used with the searching of the following words: “amino terminal pro brain type natriuretic peptide”, “pediatric pulmonary hypertension”, “congenital heart diseases”, emphasizing on original research articles published within recent 15 years and in English language. We critically analyzed and summarized the retrieved studies. Conclusion: NT-pro-BNP remains as the reliable diagnostic and prognostic marker of pulmonary hypertension and congenital heart diseases in pediatric patients. NT-pro-BNP and BNP remain as the universal marker of cardiovascular pathology in pediatric population. Improvement of their effectiveness in diagnostic workup in patients with CHD and PH undergoing surgery needs further clarification. Key words: pediatric pulmonary hypertension, N-terminal pro brain type natriuretic peptide, congenital heart disease

scholarly journals Evaluation of NT-proBNP in children with heart failure younger than 3 years old

2017 ◽  
Vol 55 (2) ◽  
pp. 69-74
Author(s):  
Daniela Iacob ◽  
Angela Butnariu ◽  
Daniel-Corneliu Leucuţa ◽  
Gabriel Samaşca ◽  
Diana Deleanu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Dilated Cardiomyopathy ◽  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Systolic Function ◽  
Heart Diseases ◽  
Functional Class ◽  
Congenital Heart Diseases

Abstract Introduction. Heart failure (HF) is characterized by neuroendocrine activation. The cardiac natriuretic hormones, including atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), together with their related pro-peptides (proANP and proBNP) represent a group of peptide hormones produced by the heart. A normal NT-proBNP level has a high negative predictive value for heart failure. The use of NT-proBNP testing is helpful in diagnosing acute HF in the emergency care setting, allowing an early and optimal treatment. The purpose of this study is to assess the prognostic value of NT-proBNP in heart failure in children younger than 3 years old and to establish whether it correlates with the NYHA/Ross functional class and left ventricle systolic function. Methods. We enrolled 24 consecutive children with HF due to congenital heart diseases and dilated cardiomyopathy. The serum levels of NT-proBNP were measured, all patients underwent echocardiography and left ventricle ejection fraction was calculated. Results. The highest median value of NT-proBNP was recorded in patients with cyanotic heart diseases (248.0 fmol/mL), p = 0.610. NT-proBNP had a negative correlation with the ejection fraction of the left ventricle: Spearman's rank correlation coefficient was −0.165. Conclusions. NT-proBNP levels correlate with the severity of HF in infants and small children younger than 3 years old with heart failure due to congenital heart diseases and dilated cardiomyopathy.

Sign in / Sign up

Export Citation Format

Share Document